BCL2 and myelodysplastic syndrome: Together, our data showed that the protein levels of individual BCL-2 family members measured by flow cytometry can be used as biomarkers to define the differential sensitivity of MDS samples to the treatment with ABT-199 in high-risk MDS/sAML patients.